NEW YORK (AP) — A federal judge on Wednesday granted a preliminary injunction to stop the U.S. Department of Labor from ...

Healthcare has seen an unprecedented surge in worker demand in recent years. There’s a call for doctors, nurses, and ...

In the UK, the importance of an accessible phlebotomy service was previously identified by the Carter Report, which called for samples to be taken at times and in places convenient to patients.37 ...

Shara Slinkard, a Southeast Missouri native with 24 years of experience, has joined EBO Labs as lead phlebotomist, overseeing ...

Blake Learns to Draw Blood with Midwest Technical Institute’s Phlebotomy Program Blake gets a lesson in phlebotomy at MTI.

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels ...

Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.

Rusfertide more than doubled the percentage of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study weeks 20-32 of the trial (76.9% vs 32.9% with ...

NEWARK, CA, USA & OSAKA, Japan & CAMBRIDGE, MA, USA I June 01, 2025 I Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control ...

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass., June 01, 2025--Protagonist Therapeutics, Inc. ("Protagonist") (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the ...